1. Home
  2. THH vs AARD Comparison

THH vs AARD Comparison

Compare THH & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THH
  • AARD
  • Stock Information
  • Founded
  • THH 2013
  • AARD 2017
  • Country
  • THH Japan
  • AARD United States
  • Employees
  • THH N/A
  • AARD N/A
  • Industry
  • THH
  • AARD Biotechnology: Pharmaceutical Preparations
  • Sector
  • THH
  • AARD Health Care
  • Exchange
  • THH Nasdaq
  • AARD Nasdaq
  • Market Cap
  • THH 270.5M
  • AARD 192.2M
  • IPO Year
  • THH 2025
  • AARD 2025
  • Fundamental
  • Price
  • THH $4.56
  • AARD $8.49
  • Analyst Decision
  • THH
  • AARD Strong Buy
  • Analyst Count
  • THH 0
  • AARD 5
  • Target Price
  • THH N/A
  • AARD $32.60
  • AVG Volume (30 Days)
  • THH 715.5K
  • AARD 86.7K
  • Earning Date
  • THH 01-01-0001
  • AARD 08-13-2025
  • Dividend Yield
  • THH N/A
  • AARD N/A
  • EPS Growth
  • THH N/A
  • AARD N/A
  • EPS
  • THH 0.02
  • AARD N/A
  • Revenue
  • THH $20,390,561.00
  • AARD N/A
  • Revenue This Year
  • THH N/A
  • AARD N/A
  • Revenue Next Year
  • THH N/A
  • AARD N/A
  • P/E Ratio
  • THH $292.44
  • AARD N/A
  • Revenue Growth
  • THH 14.93
  • AARD N/A
  • 52 Week Low
  • THH $4.24
  • AARD $4.88
  • 52 Week High
  • THH $12.00
  • AARD $19.58
  • Technical
  • Relative Strength Index (RSI)
  • THH N/A
  • AARD N/A
  • Support Level
  • THH N/A
  • AARD N/A
  • Resistance Level
  • THH N/A
  • AARD N/A
  • Average True Range (ATR)
  • THH 0.00
  • AARD 0.00
  • MACD
  • THH 0.00
  • AARD 0.00
  • Stochastic Oscillator
  • THH 0.00
  • AARD 0.00

About AARD Aardvark Therapeutics Inc. Common Stock

Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Share on Social Networks: